There is a hieroglyph regarded as “shemshemet” which means Cannabis. Many other ancient societies have left references to this plant found in ancient Sumerian, Chinese, Persian, Greek, and Hebrew texts. The image below provides depictions of shemshemet, bhang, kaneh bosem, and others.
Some remain unconvinced that Cannabis was widely used in Egypt during ancient times. As references to Cannabis appear and disappear throughout Egyptian records, a term referred to as ‘Cannabis Interuptus.’ This disappearing act is easy to understand as the papyrus is very delicate and hard to preserve given the human propensity for constant war, invasion, conflict, and the occasional overthrow of a dictatorial regime. Although, the disappearance or shortage of herbal products is something we can see today as Egypt suffered a “Hash Crisis”, a sort of hash famine swept the land.
Back to the ancient evidence, pollen has been been detected in ancient soil samples and mummies. Also, by the 9th and 10th century, Egyptian medicine became Islamic medicine. Despite Sharia law banning all intoxicants, the plant in “hashish form” continued to be used for its powerful medicinal qualities. The term for the plant and its products changed over time, adding another level of confusion, in Islamic medicine it was no longer referred to as “shemshemet” but instead was called “hashish, or shadanaj,the Royal grain.”
Mr.Reichenbach provided background on stroke, stating that it is the 3rd cause of death in this country, and 85% of those strokes are of the ischemic variety. During an ischemic event there is a hyper-immune response resulting in the recruitment of immune cells that kill brain tissue. Cannabinoids have been shown to modulate the immune system, notably the Tuma lab has published data on the CB2 receptor’s anti-inflammatory effects. Activating the CB2 receptor decreases the migration of hyper-immune cells to the brain. The more brain you save, the more you save someone from disabilities or death.
When asked about the implications of these findings on a cannabinoid that could be a potential stroke therapy, Mr.Reichenbach replied that the results of his work and others is promising, as far as the big picture goes, he said, “at the end of the day, it matters how much brain tissue we save.”
And just in case you were wondering, THC, the active ingredient in Cannabis, activates both the CB1 and CB2 receptor.
If you’re a Temple undergrad, graduate or medical student you may enroll in the Cannabinoid Discussion Group for class credit. This makes Temple one of the only, if not THE only insitution in the country to offer a course on cannabinoids.
Over the last decade there have been numerous publications demonstrating the anti-cancer effects of plant and synthetic cannabinoids. Notably, the main ingredient of Cannabis, THC (tetrahydrocannabinol), has demonstrated the ability to kill multiple types of cancers in a variety of cancer research models. CBD (cannabidiol), another common plant component, has also shown the ability to kill cancer cells, recently it has been used to successfully treat breast cancer in a mouse research model of the disease.
Certain types of brain cancer appear to be vulnerable to cannabinoids such as THC and CBD. Scientific research has demonstrated that THC and other cannabinoids can kill extremely aggressive brain cancers known as glioblastoma multiforme (GBM) or grade IV astrocytomas. Researchers have also experimented with combining different cananbinoids for the treatment of aggressive brain cancers. So far, the results have been extremely promising. There is a need for new treatments for GBMs, as current treatments for these cancers can extend life for up to 15 months, if you’re lucky.
The study was conducted in Spain, and the experiments analyzing the effects of cannabinoids were conducted with tumors or brain cancer cells from human samples and a tumor xenograft mouse model. A tumor xenograft model is basically a cancer that is induced into an animal that has a compromised immune system. This allows researchers to give a mouse a tumor consisting of human cells, thus a promising anti-cancer treatment can be tested on a human tumor in a more natural environment, than a petri dish.
The plant cannabinoids used for this study were “kindly provided by GW pharmaceuticals.” THC and CBD were also provided as plant extracts or “botanical drug substances,” meaning they contained small amounts of other cannabinoids. Allowing these researchers to construct a custom anti-cancer, Sativex-like substance. Other synthetic cannabinoids such as SR141716A and SR144528 were donated by Sonafi-Aventis.
The figure below shows that THC and TMZ can drastically inhibit the size of tumor.
In the following figure, the authors also examined combinations of THC,CBD, TMZ , and SAT-L (a “botonical drug substance” or extract containing a 1:1 ratio of THC and CBD, 7.5mg each). Interestingly their results also showed that TMZ resistant cells, can be killed by cannabinoids or in combination with cannabinoids.
The researchers conclude that:
“Taken together, our observations support that the administration of cannabinoids, and in particular of Sativex, which is currently used for palliative applications in patients with cancer and multiple sclerosis, alone or in combination with TMZ, could be of potential interest for the management of GBM.”
Cannabis-based medicines are most often prescribed to increase quality of life or treat symptoms of disease. As research continues on this ancient medicine, scientific data suggests that cannabinoids are not only promising treatments but represent potential cures.
As early as 5,000 years ago Cannabis was noted for its effects on the central nervous system[1]. This often manifested in the form of pain relief, appetite stimulation, and sedation (Iverson 2000). Medicinal Cannabis preparations were widely used in western medicine during the 19th century. At the time it was no secret that pharmaceutical preparations of Cannabis were variable. As the active ingredient was not known, quality control was virtually impossible, and this is in part why the plant fell out of use.
During the Victorian era, many plants were extracted for their unique properties, namely alkaloids. These plant chemists were successful because the alkaloids they were targeting are water soluble organic bases that form crystalline solids when combined with acids. Among the medicinal compounds isolated in the 19th century were quinine, morphine, and cocaine. These were major advances in plant chemistry. The molecules on the cannabis plant, however, are almost completely insoluble in water. The chemical nature of cannabinoids prevented early Victorian scientists from making efficient extracts of these polar compounds. The active ingredient, THC, wasn’t isolated and identified until 1964.
In the 1990s, researchers made discoveries essential for the establishment of the cannabinoid research field. By the end of the decade scientists discovered two distinct cannabinoid receptors (i.e., CB1 and CB2), isolated endogenous cannabinoids (e.g.,Anandamide and 2-Arachidonylglycerol), synthesized a cadre of ligands, and generated cannabinoid receptor knockout mice (Matsuda 1990, Gerard 1990, Zimmer 1999). Efforts to identify and clone the CB1 receptor also demonstrate that the CB1 receptor is one of the most abundant proteins in the brain. Thus, cannabinoid receptors became an attractive target for drug development. The availability of synthetic THC and novel analogs has allowed researchers to begin characterizing the role of this neuronal G-protein coupled receptor. The sum of all knowledge on how cannabinoid receptors and their ligands work together in mammals is referred to as the endocannabinoid system.
[1] Evidence for the medicinal use of Cannabis goes back to the emperor Chen Nung (the father of Chinese agriculture), a discoverer of medicinal plants, and also taught his people how to cultivate grains. Chen Nung is believed to be the author of the oldest known Chinese pharmacopoeia, in which, he writes about the medical use of Cannabis for rheumatism, menstrual fatigue, malaria, constipation, and absentmindedness.
As New Jersey continues to revise its medical Cannabis laws, the feasibility of implementing the law as it is written may be impossible. TheNJ DHSS claim they are following science but do not site a single scientific study. They claim the law is similar to the program at the University of Mississippi (UMiss), justifying the proposed limit on 10% THC in Cannabis plants grown for New Jersey’s program. New Jersey claims there regulation is based on the UMiss program but New Jersey’s laws. It’s true that the UMiss program doesn’t provide Cannabis cigarettes with more than 10% THC. However, the New Jersey law makers leave out the reasoning behind this. The reason UMiss doesn’t supply Cannabis cigarettes with high THC content is because the mixture will get stuck in the cigarette rolling machine.
“The cigarettes are not made here, unless there’s a requirement for high-potency material, which doesn’t lend itself to mechanized production of cigarettes, because it gets resinous and gums the machine. We use a small hand roller for that,” says ElSohly. “But if we need them in bulk, like say 60,000 cigarettes, we have a subcontract with a company in North Carolina.”
Other differences exist between New Jersey’s law and the Federal program. For instance, under the Federal program Dr.Elsohly can process Cannabis into cigarettes, patches, suppositories, etc. Dr.Elsohly also grows high potency varieties for research and in doing so has discovered about 20 new cannabinoids. Every government sponsored Medical Cannabis program in the world allows the Cannabis plant to be homogenized and thus standardized.
Please Donate to Cannabination. Every dollar helps keep the site going!
Thanks,
Jahan
Disclaimer: The information is not intended to treat and diagnose any illness. The views expressed are those of the author and do not reflect those of any University or its affiliates.
Recently, a Doctor came out against using Cannabis for the treatment of HIV/AIDS. Among oncologists, his opinion is probably in the minority. This Doctor claims that no HIV patients he knows, would benefit from Cannabis. Unfortunately, the Doctor only discussed his opinion and did not site any current research from controlled studies to support his stance. Current research in HIV/AIDS and cannabinoids has been promising– practically every clinical trial that has looked at HIV/AIDS and THC has shown that cannabinoids may help patients.
Later, other researchers would show, in a similar group of HIV patients, that smoked Cannabis can modulate pain where conventional opiates were ineffective. The beneficial effect of cannabis on HIV/AIDS symptoms in humans has inspired other researches to take a closer look at the mechanisms behind these effects.
A research team from Virginia Commonweatlh University showed that natural Delta9- THC and synthetic CP-55,940 could inhibit the HIV inflammatory response through the Cannabinoid Type II (CB2) Receptor. Once HIV invades a cell, the virus makes the cell secrete many proteins to attract other immune cells and this leads to the ongoing infection of other cells. One such protein called Tat is important for viral replication and gene expression; the effects of this protein on cell migration appear to be inhibited by both synthetic and natural cannabinoids. The main finding of these researchers is that cannabinoids can slow the migration of uninfected cells towards the Tat protein and thus could inhibit the HIV infection process and the associated inflammation.
Another research group also thought that the previous worked on HIV and cannabinoids was unbelievable. So, they sought to see if THC made the disease worse in monkeys. The researchers infected monkeys with SIV and studied them for 1 year. SIV is the equivalent of HIV in humans. Their research was published in September 2010 and the entire article can be found here:Molina Article on THC attenuates SIV.
Note that each monkey costs around $8,000.00 for the research study.
The researcher demonstrated that THC slows the progression of HIV in primates. See Figure 4 below from the Article by Molina et al.
In Figure 4, there are two groups of monkeys. The solid line is the THC group and the dotted line is the control group (no drug). Within 11 months, 80% of the control group died (dotted line). In the group that received the drug THC, no deaths were reported.
The authors conclude :”this study is the first to report in vivo experimental data demonstrating that chronic THC initiated prior to, and continued throughout the asymptomatic phase of SIV infection, does not impair the host’s ability to control viral load, and does not increase morbidity and mortality from the infection…THC treatment clearly did not increase disease progression, and indeed resulted in generalized attenuation of the classic markers of SIV disease (set point viral load/viral level in general)…based on our results and reports in the literature, we speculate that retention of body mass,attenuation of viral replication, and an overall immunosuppressant effect of cannabinoids may contribute to the amelioration of SIV disease progression seen in our study.”
However, THC is only part of the story. There are over 500 compounds on the Cannabis plant and some of these compounds may contain powerful medical properties which could treat a variety of diseases including Cancer and HIV/AIDS. For instance researchers have found that Cannabis extracts which contain Denbinobin can inhibit HIV replication in a petri dish. Denbinobin is found on the Cannabis and other plants as well.
The therapeutic promise of this plant remains high and some states have medical laws allowing the use of Cannabis for HIV. Furthermore, Marinol or synthetic THC in a capsule remains available by prescription in the U.S. GW pharmaceuticals has an extract available for the treatment of HIV symptoms but it is not allowed in the United States. It is available in Canada, UK, Spain, and soon to be available in South America.
Disclaimer: The information is not intended to treat and diagnose any illness. The views expressed are those of the author and do not reflect those of any University or its affiliates.
SIV THC Figure 4
